Anaconda Biomed to close a €20m investment round led by Asabys Partners

Anaconda Biomed, a Barcelona, Spain-based medical device company raised €20 million ($22M)) in a new investment round.

The round was led by the Spanish venture capital firm Asabys Partners, through its fund Sabadell Asabys Health Innovation Investments, and included existing investors Ysios Capital, Omega Funds and Innogest.

The money will be used for clinical studies, regulatory submissions, product development and manufacturing scale-up.

Anaconda Biomed, led by CEO Francois Salmon, develops next-generation thrombectomy systems to treat ischemic stroke. Anaconda’s advanced thrombectomy System consists of a delivery catheter, a unique, funnel-shaped aspiration catheter and a stent retriever. The funnel of the system can self-expand and conform to the artery diameter up to 5mm to arrest the blood flow in the local area, facilitating extraction of full thrombus without fragmentation.